Millennium Management LLC Sells 60,935 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Millennium Management LLC reduced its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 38.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,178 shares of the company’s stock after selling 60,935 shares during the period. Millennium Management LLC owned approximately 0.18% of Voyager Therapeutics worth $545,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of VYGR. Cubist Systematic Strategies LLC bought a new position in Voyager Therapeutics during the 4th quarter worth approximately $29,000. Tower Research Capital LLC TRC grew its stake in shares of Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after buying an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management grew its position in Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after purchasing an additional 2,444 shares during the last quarter. Oxford Asset Management LLP bought a new position in Voyager Therapeutics in the 4th quarter valued at approximately $60,000. Finally, Virtu Financial LLC bought a new position in Voyager Therapeutics during the 4th quarter valued at about $100,000. Institutional investors own 48.03% of the company’s stock.

Insider Buying and Selling at Voyager Therapeutics

In related news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the completion of the transaction, the chief executive officer now owns 430,931 shares in the company, valued at $1,478,093.33. The trade was a 2.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.39% of the stock is owned by corporate insiders.

Voyager Therapeutics Price Performance

Shares of NASDAQ:VYGR opened at $3.54 on Monday. Voyager Therapeutics, Inc. has a 1 year low of $2.65 and a 1 year high of $9.55. The firm has a market capitalization of $195.89 million, a PE ratio of 4.99 and a beta of 0.82. The business’s 50 day moving average price is $3.23 and its 200-day moving average price is $4.44.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.18). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $6.47 million for the quarter, compared to analysts’ expectations of $13.55 million. As a group, analysts expect that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group lowered their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 target price on shares of Voyager Therapeutics and gave the stock an “overweight” rating in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Voyager Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $13.39.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.